Global Multi-omics Market - 2025-2033

The global multi-omics market reached US$ 3.25 Billion in 2024 and is expected to reach US$ 33.25 Billion by 2033, growing at a CAGR of 26.1% during the forecast period 2025-2033.

Multiomics is a multidisciplinary approach that integrates various omics technologies, aiding in the discovery of biomarkers, understanding disease mechanisms, and advancing personalized medicine by analyzing data from various molecular layers.

The global multiomics market is experiencing significant growth due to precision medicine adoption, drug discovery research, and sequencing technologies. Key drivers include demand for integrated biological data analysis, government funding, and healthcare and biotechnology applications. North America leads the market due to strong research infrastructure, while Asia-Pacific is emerging as a lucrative region. Major players like Thermo Fisher Scientific, Illumina, and QIAGEN are driving innovation in this field.

Market Dynamics: Drivers & Restraints

Rising Adoption of Precision Medicine

The global multiomics market is driven by the growing focus on precision medicine, which allows for a deeper understanding of individual genetic, proteomic, and metabolic profiles. Governments and healthcare organizations are investing heavily in multiomics research to develop personalized therapies for complex diseases like cancer and neurological disorders. The integration of artificial intelligence and bioinformatics accelerates drug discovery and patient-specific treatment strategies.

For instance, in January 2025, Enhanc3D Genomics, a pioneer in 3D genomics technology, launched a suite of integrated multi-omics solutions to enhance drug discovery precision. The solutions, based on the company's proprietary 3D genomics platform, provide partners with a comprehensive end-to-end solution to support decision-making throughout the drug discovery and development process.

Data Complexity and Integration

The global multiomics market faces challenges due to data complexity and integration, as it generates vast heterogeneous data from genomics, transcriptomics, proteomics, and metabolomics. This requires advanced computational tools for meaningful interpretation, standardization across platforms, and interoperability between databases. Ensuring data accuracy, reproducibility, and scalability requires high-performance computing and sophisticated algorithms, which limits accessibility for smaller research organizations and clinical applications.

Segment Analysis

The global multi-omics market is segmented based on product & service, technology, application, end-user, and region.

Product & Service:

The instruments from the product & service segment are expected to dominate the multi-omics market with the highest market share.

Multiomics instruments, including NGS platforms, mass spectrometers, and microarrays, are specialized lab equipment used in various omics fields for precise detection, quantification, and characterization of biological molecules, enabling high-throughput data generation and drug development.

Instruments are vital in the global multiomics market, enabling precise analysis of biological molecules in genomics, transcriptomics, proteomics, and metabolomics. Advanced sequencing platforms, mass spectrometers, chromatography systems, and imaging technologies generate high-resolution data, facilitating molecular profiling, biomarker discovery, and disease mechanism studies. Continuous innovations in automation, miniaturization, and high-throughput analysis improve efficiency and accessibility, making multiomics technologies more accessible for research institutes, biotechnology companies, and clinical laboratories.

For instance, in June 2024, Mission Bio launched the Tapestri Single-cell Multiple Myeloma Multiomics Solution, a product suite designed to revolutionize multiple myeloma research and therapeutic development. The suite offers comprehensive insights into disease evolution and biology at the single-cell level, enabling researchers and drug developers to understand therapy resistance and disease relapse at the subclonal level. This new product suite will enhance the understanding of disease progression and treatment resistance.

Geographical Analysis

North America is expected to hold a significant position in the multi-omics market with the highest market share

North America leads the global multi-omics market due to its significant product launches, robust research infrastructure, government funding, and key industry players. The region's biotechnology and pharmaceutical sectors invest in multi-omics technologies for drug discovery, precision medicine, and clinical diagnostics. Advanced sequencing platforms, bioinformatics tools, and AI-driven analytics enhance research capabilities.

For instance, in September 2024, The Translational Genomics Research Institute (TGen), part of the City of Hope, launched the Center for Spatial Multi-Omics (COSMO), a service center aimed at transforming biomedical research through spatial biology. COSMO offers services to visualize and map molecular data at the single-cell level within tissues, preserving important cellular environments and structures for histological analysis. Advanced technologies enable researchers to examine thousands of RNA targets in detail.

Moreover, partnerships and collaborations between academic institutions and biotech firms accelerate innovation which indeed helps the region to grow during the forecast period. For instance, in January 2024, Thermo Fisher Scientific Inc. and Akoya Biosciences signed a license and distribution agreement to provide a comprehensive solution for spatial multi-omics workflows, simplifying the whole-slide, multi-omics imaging process and examining protein and RNA, crucial for cancer research fields.

Furthermore, in January 2024, BD partnered with Hamilton Company to create robotics-compatible and automated reagent kits for large-scale single-cell multi-omics experiments, aiming to standardize and minimize human error.

Competitive Landscape

The major global players in the multi-omics market include BD (Becton, Dickinson, and Company), Thermo Fisher Scientific Inc., Illumina, Inc., Danaher Corporation, Bruker Corporation, QIAGEN N.V, Agilent Technologies, Inc., Genedata, Shimadzu Corporation, and Element Biosciences among others.

Key Developments

• In May 2024, QIAGEN launched its QIAseq Multimodal DNA/RNA Library Kit, which enables the preparation of DNA and RNA libraries for next-generation sequencing, including whole genome sequencing and whole transcriptome sequencing, and downstream target enrichment using hybrid-capture from a single sample.
• In June 2023, Singleton, a trusted partner for scientists and clinicians, launched two new single-cell multi-omics products: NEO and Python Junior. These portable instruments are designed to fit into any laboratory and deliver accurate and reproducible results. The NEO library processing system and Python Junior tissue dissociation instrument aim to make single-cell sequencing accessible for every laboratory, ensuring accurate and reproducible results for researchers and clinicians alike.

Why Purchase the Report?

• Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global multi-omics market report delivers a detailed analysis with 70 key tables, more than 65 visually impactful figures and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.